MCMDA: Matrix completion for MiRNA-disease association prediction

Nowadays, researchers have realized that microRNAs (miRNAs) are playing a significant role in many important biological processes and they are closely connected with various complex human diseases. However, since there are too many possible miRNA-disease associations to analyze, it remains difficult to predict the potential miRNAs related to human diseases without a systematic and effective method. In this study, we developed a Matrix Completion for MiRNA-Disease Association prediction model (MCMDA) based on the known miRNA-disease associations in HMDD database. MCMDA model utilized the matrix completion algorithm to update the adjacency matrix of known miRNA-disease associations and furthermore predict the potential associations. To evaluate the performance of MCMDA, we performed leave-one-out cross validation (LOOCV) and 5-fold cross validation to compare MCMDA with three previous classical computational models (RLSMDA, HDMP, and WBSMDA). As a result, MCMDA achieved AUCs of 0.8749 in global LOOCV, 0.7718 in local LOOCV and average AUC of 0.8767+/−0.0011 in 5-fold cross validation. Moreover, the prediction results associated with colon neoplasms, kidney neoplasms, lymphoma and prostate neoplasms were verified. As a consequence, 84%, 86%, 78% and 90% of the top 50 potential miRNAs for these four diseases were respectively confirmed by recent experimental discoveries. Therefore, MCMDA model is superior to the previous models in that it improves the prediction performance although it only depends on the known miRNA-disease associations.

[1]  Ujjwal Maulik,et al.  Development of the human cancer microRNA network , 2010 .

[2]  Xing Chen,et al.  Long non-coding RNAs and complex diseases: from experimental results to computational models , 2016, Briefings Bioinform..

[3]  Arndt Hartmann,et al.  The proto‐oncogene ERG is a target of microRNA miR‐145 in prostate cancer , 2013, The FEBS journal.

[4]  Qionghai Dai,et al.  WBSMDA: Within and Between Score for MiRNA-Disease Association prediction , 2016, Scientific Reports.

[5]  Xing Chen,et al.  Sequence-based prediction of protein-protein interactions using weighted sparse representation model combined with global encoding , 2016, BMC Bioinformatics.

[6]  Jiaojiao Lin,et al.  Correction: MicroRNAs Are Involved in the Regulation of Ovary Development in the Pathogenic Blood Fluke Schistosoma japonicum , 2016, PLoS pathogens.

[7]  M. Nickerson,et al.  MicroRNA-23b* targets proline oxidase, a mitochondrial tumor suppressor protein in renal cancer , 2010, Oncogene.

[8]  Emmanuel J. Candès,et al.  Exact Matrix Completion via Convex Optimization , 2009, Found. Comput. Math..

[9]  Frank J. Slack,et al.  The Role of MicroRNAs in Cancer , 2006, The Yale journal of biology and medicine.

[10]  Gerald Hoefler,et al.  miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. , 2012, Carcinogenesis.

[11]  Qionghai Dai,et al.  RBMMMDA: predicting multiple types of disease-microRNA associations , 2015, Scientific Reports.

[12]  Long Cui,et al.  Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. , 2012, Saudi medical journal.

[13]  Virginia Pascual,et al.  How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets , 2008, Immunological reviews.

[14]  Xing Chen.  KATZLDA: KATZ measure for the lncRNA-disease association prediction , 2015, Scientific Reports.

[15]  Emmanuel J. Candès,et al.  A Singular Value Thresholding Algorithm for Matrix Completion , 2008, SIAM J. Optim..

[16]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[17]  Xing Chen,et al.  Predicting lncRNA-disease associations and constructing lncRNA functional similarity network based on the information of miRNA , 2015, Scientific Reports.

[18]  Aung Ko Win,et al.  Colon and Rectal Cancer Survival by Tumor Location and Microsatellite Instability: The Colon Cancer Family Registry , 2013, Diseases of the colon and rectum.

[19]  Ying Ju,et al.  Prediction of MicroRNA-disease Associations by Matrix Completion , 2016 .

[20]  Jia Song,et al.  [Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance]. , 2012, Zhongguo shi yan xue ye xue za zhi.

[21]  G. V. Vande Woude,et al.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. , 2001, The American journal of pathology.

[22]  D Manojlović,et al.  [Therapeutic value of transcatheter embolization in malignant tumors of the renal parenchyma]. , 1986, Srpski arhiv za celokupno lekarstvo.

[23]  Rolf Larsson,et al.  In vitro and in vivo activity of melflufen (J1)in lymphoma , 2016, BMC Cancer.

[24]  J. Richie,et al.  Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma. , 1998, Urology.

[25]  Xing Chen,et al.  IRWRLDA: improved random walk with restart for lncRNA-disease association prediction , 2016, Oncotarget.

[26]  Changning Liu,et al.  dbDEMC: a database of differentially expressed miRNAs in human cancers , 2010, BMC Genomics.

[27]  G. Golub,et al.  Inexact and preconditioned Uzawa algorithms for saddle point problems , 1994 .

[28]  A W Partin,et al.  Family history facilitates the early diagnosis of prostate carcinoma , 1997, Cancer.

[29]  Salvatore Alaimo,et al.  ncPred: ncRNA-Disease Association Prediction through Tripartite Network-Based Inference , 2014, Front. Bioeng. Biotechnol..

[30]  Q. Cui,et al.  Prediction of Disease-Related Interactions between MicroRNAs and Environmental Factors Based on a Semi-Supervised Classifier , 2012, PloS one.

[31]  Jan Gorodkin,et al.  Protein-driven inference of miRNA–disease associations , 2013, Bioinform..

[32]  Xing Chen.  miREFRWR: a novel disease-related microRNA-environmental factor interactions prediction method. , 2016, Molecular bioSystems.

[33]  Alejandro Pazos-Sierra,et al.  Diagnostic and treatment delay, quality of life and satisfaction with care in colorectal cancer patients: a study protocol , 2013, Health and Quality of Life Outcomes.

[34]  A Correspondent in Cell Biology,et al.  Gene Regulation , 1967, Nature.

[35]  井上 泰介.  Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer , 2012 .

[36]  Xing Chen,et al.  HGIMDA: Heterogeneous graph inference for miRNA-disease association prediction , 2016, Oncotarget.

[37]  Xing Chen,et al.  Novel human lncRNA-disease association inference based on lncRNA expression profiles , 2013, Bioinform..

[38]  Xia Li,et al.  Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes , 2013, BMC Systems Biology.

[39]  M. Nishikido,et al.  Multifocal transitional cell carcinoma associated with renal cell carcinoma in a patient on long-term haemodialysis. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  T. Zhao,et al.  Re‐expression of microRNA‐150 induces EBV‐positive Burkitt lymphoma differentiation by modulating c‐Myb in vitro , 2013, Cancer science.

[41]  Xing Chen,et al.  Semi-supervised learning for potential human microRNA-disease associations inference , 2014, Scientific Reports.

[42]  Yadong Wang,et al.  Prioritization of disease microRNAs through a human phenome-microRNAome network , 2010, BMC Systems Biology.

[43]  Xing Chen,et al.  FMLNCSIM: fuzzy measure-based lncRNA functional similarity calculation model , 2016, Oncotarget.

[44]  Yun Xiao,et al.  Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[45]  Yun Xiao,et al.  Prioritizing candidate disease miRNAs by integrating phenotype associations of multiple diseases with matched miRNA and mRNA expression profiles. , 2014, Molecular bioSystems.

[46]  Kishore Guda,et al.  The noncoding RNA, miR‐126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3‐kinase signaling and is frequently lost in colon cancers , 2008, Genes, chromosomes & cancer.

[47]  A. Clark,et al.  Impact of microRNA regulation on variation in human gene expression , 2012, Genome research.

[48]  Yufei Huang,et al.  Prediction of microRNAs Associated with Human Diseases Based on Weighted k Most Similar Neighbors , 2013, PloS one.

[49]  M. S. Abdullah,et al.  Colorectal cancer: incidence and trend in Brunei Darussalam. , 2009, Singapore medical journal.

[50]  Qing Liao,et al.  Predicting Unknown Interactions Between Known Drugs and Targets via Matrix Completion , 2016, PAKDD.

[51]  Zhu-Hong You,et al.  ILNCSIM: improved lncRNA functional similarity calculation model , 2016, Oncotarget.

[52]  Yi Pan,et al.  LDAP: a web server for lncRNA-disease association prediction. , 2016, Bioinformatics.

[53]  Ding Yuan,et al.  Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and Colorectal Cancer Risk , 2012, PloS one.

[54]  Renato Baserga,et al.  Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells* , 2007, Journal of Biological Chemistry.

[55]  Xiangxiang Zeng,et al.  Integrative approaches for predicting microRNA function and prioritizing disease-related microRNA using biological interaction networks , 2016, Briefings Bioinform..

[56]  Young-Kook Kim,et al.  Extracellular microRNAs as Biomarkers in Human Disease , 2015, Chonnam medical journal.

[57]  E. Izaurralde,et al.  Getting to the Root of miRNA-Mediated Gene Silencing , 2008, Cell.

[58]  C. Llave,et al.  Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA , 2002, Science.

[59]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[60]  Xing Chen,et al.  RWRMDA: predicting novel human microRNA-disease associations. , 2012, Molecular bioSystems.

[61]  M. Dobbelstein,et al.  E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis , 2010, Cell Death and Differentiation.

[62]  Zhu-Hong You,et al.  Detection of Interactions between Proteins through Rotation Forest and Local Phase Quantization Descriptors , 2015, International journal of molecular sciences.

[63]  Xia Li,et al.  Prediction of potential disease-associated microRNAs based on random walk , 2015, Bioinform..

[64]  Yang Li,et al.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..

[65]  Qionghai Dai,et al.  Constructing lncRNA functional similarity network based on lncRNA-disease associations and disease semantic similarity , 2015, Scientific Reports.

[66]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[67]  Noam Shomron,et al.  Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. , 2012, Pharmacogenomics.

[68]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[69]  Norma I Rodríguez-Malavé,et al.  MicroRNAs in B cell development and malignancy , 2012, Journal of Hematology & Oncology.

[70]  C. Pasquier,et al.  Prediction of miRNA-disease associations with a vector space model , 2016, Scientific Reports.

[71]  Amir Gamliel,et al.  “Seq-ing” Insights into the Epigenetics of Neuronal Gene Regulation , 2013, Neuron.

[72]  Punam Pahwa,et al.  Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects , 2009, BMC Cancer.